Skip to main content

Extended Human Papillomavirus Genotyping to Predict Progression to High-Grade Cervical Precancer: A Prospective Cohort Study in the Southeastern United States.

Publication ,  Journal Article
Bukowski, A; Hoyo, C; Hudgens, MG; Brewster, WR; Valea, F; Bentley, RC; Vidal, AC; Maguire, RL; Schmitt, JW; Murphy, SK; North, KE; Smith, JS
Published in: Cancer Epidemiol Biomarkers Prev
August 2, 2022

BACKGROUND: High-risk human papillomavirus (hrHPV) testing is utilized in primary cervical cancer screening, generally along with cytology, to triage abnormalities to colposcopy. Most screening-based hrHPV testing involves pooled detection of any hrHPV or of HPV16/18. Cervical neoplasia progression risks based on extended hrHPV genotyping-particularly non-16/18 hrHPV types-are not well characterized. HPV genotype-specific incidence of high-grade cervical intraepithelial neoplasia or more severe (CIN2+) following an abnormal screening result was examined. METHODS: We assessed a US-based prospective, multiracial, clinical cohort of 343 colposcopy patients with normal histology (n = 226) or CIN1 (n = 117). Baseline cervical samples underwent HPV DNA genotyping, and participants were followed up to 5 years. Genotype-specific CIN2+ incidence rates (IR) were estimated with accelerated failure time models. Five-year CIN2+ risks were estimated nonparametrically for hierarchical hrHPV risk groups (HPV16; else HPV18/45; else HPV31/33/35/52/58; else HPV39/51/56/59/68). RESULTS: At enrollment, median participant age was 30.1 years; most (63%) were hrHPV-positive. Over follow-up, 24 participants progressed to CIN2+ (7.0%). CIN2+ IR among hrHPV-positive participants was 3.4/1,000 person-months. CIN2+ IRs were highest for HPV16 (8.3), HPV33 (7.8), and HPV58 (4.9). Five-year CIN2+ risk was higher for HPV16 (0.34) compared with HPV18/45 (0.12), HPV31/33/35/52/58 (0.12), and HPV39/51/56/59/68 (0.16) (P = 0.05). CONCLUSIONS: Non-16/18 hrHPV types are associated with differential CIN2+ progression rates. HPV16, 33, and 58 exhibited the highest rates over 5 years. HPV risk groups warrant further investigation in diverse US populations. IMPACT: These novel data assessing extended HPV genotyping in a diverse clinical cohort can inform future directions to improve screening practices in the general population.

Duke Scholars

Published In

Cancer Epidemiol Biomarkers Prev

DOI

EISSN

1538-7755

Publication Date

August 2, 2022

Volume

31

Issue

8

Start / End Page

1564 / 1571

Location

United States

Related Subject Headings

  • Uterine Cervical Neoplasms
  • Prospective Studies
  • Papillomavirus Infections
  • Papillomaviridae
  • Humans
  • Human papillomavirus 18
  • Human papillomavirus 16
  • Genotype
  • Female
  • Epidemiology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Bukowski, A., Hoyo, C., Hudgens, M. G., Brewster, W. R., Valea, F., Bentley, R. C., … Smith, J. S. (2022). Extended Human Papillomavirus Genotyping to Predict Progression to High-Grade Cervical Precancer: A Prospective Cohort Study in the Southeastern United States. Cancer Epidemiol Biomarkers Prev, 31(8), 1564–1571. https://doi.org/10.1158/1055-9965.EPI-22-0054
Bukowski, Alexandra, Cathrine Hoyo, Michael G. Hudgens, Wendy R. Brewster, Fidel Valea, Rex C. Bentley, Adriana C. Vidal, et al. “Extended Human Papillomavirus Genotyping to Predict Progression to High-Grade Cervical Precancer: A Prospective Cohort Study in the Southeastern United States.Cancer Epidemiol Biomarkers Prev 31, no. 8 (August 2, 2022): 1564–71. https://doi.org/10.1158/1055-9965.EPI-22-0054.
Bukowski A, Hoyo C, Hudgens MG, Brewster WR, Valea F, Bentley RC, et al. Extended Human Papillomavirus Genotyping to Predict Progression to High-Grade Cervical Precancer: A Prospective Cohort Study in the Southeastern United States. Cancer Epidemiol Biomarkers Prev. 2022 Aug 2;31(8):1564–71.
Bukowski, Alexandra, et al. “Extended Human Papillomavirus Genotyping to Predict Progression to High-Grade Cervical Precancer: A Prospective Cohort Study in the Southeastern United States.Cancer Epidemiol Biomarkers Prev, vol. 31, no. 8, Aug. 2022, pp. 1564–71. Pubmed, doi:10.1158/1055-9965.EPI-22-0054.
Bukowski A, Hoyo C, Hudgens MG, Brewster WR, Valea F, Bentley RC, Vidal AC, Maguire RL, Schmitt JW, Murphy SK, North KE, Smith JS. Extended Human Papillomavirus Genotyping to Predict Progression to High-Grade Cervical Precancer: A Prospective Cohort Study in the Southeastern United States. Cancer Epidemiol Biomarkers Prev. 2022 Aug 2;31(8):1564–1571.

Published In

Cancer Epidemiol Biomarkers Prev

DOI

EISSN

1538-7755

Publication Date

August 2, 2022

Volume

31

Issue

8

Start / End Page

1564 / 1571

Location

United States

Related Subject Headings

  • Uterine Cervical Neoplasms
  • Prospective Studies
  • Papillomavirus Infections
  • Papillomaviridae
  • Humans
  • Human papillomavirus 18
  • Human papillomavirus 16
  • Genotype
  • Female
  • Epidemiology